ClinicalTrials.gg
CompletedNCT00325195Updated Feb 28, 2011Results posted

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

A Phase 3 interventional study of placebo and pegloticase in Gout, sponsored by Savient Pharmaceuticals. Completed at 56 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-28.

Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
3rd of 14
225 · median 93
Started
2006
with 1 other
Phase 3
4 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
4 of 14
Savient Pharmaceuticals

Among the 14 studies testing pegloticase in Gout, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 3rd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.

Read the detailed description

The primary objective of each of the studies is to demonstrate superiority in the response rate (control of uric acid levels to below 6 mg/dL) in the PEG-uricase treatment groups compared to the placebo-control group.

While reduction or resolution of tophi have been reported in the setting of prolonged urate-lowering therapy, there is photographic and additional anecdotal evidence from the Phase 2 PEG-uricase study of resolution or significant reduction of tophi after 3 months of therapy. Therefore, an assessment of changes in tophi over time will be conducted through the use of digital photographs obtained in a standardized manner from all subjects during the study. The effect on other clinical outcomes, including quality of life, health-related disability measures, gout flares and the number of swollen and tender joints will also be compared between the treatment groups and control group. Subjects will be randomized to one of the three treatment arms in a 2:2:1 ratio: 8 mg PEG-uricase every 2 weeks; 8 mg PEG-uricase every 4 weeks; or placebo. All subjects will receive an intravenous infusion (PEG-uricase or placebo) every two weeks in order to maintain the blind throughout the study. Study duration is approximately 26 weeks, including two weeks for screening and 24 weeks (6 months) of treatment.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients of either gender, age 18 or older ( no upper age limit).
  2. Patient is hyperuricemic: screening serum uric acid must be ≥8 mg/dL.
  3. Patient has symptomatic gout (presence of at least 3 gout flares in the 18 months prior to entry, or at least one gout tophus, or gouty arthritis).
  4. Conventional therapy is or has been ineffective in this patient, i.e., patient has a history (either by medical record or patient interview) of or of failure to normalize SUA with at least 3 months treatment with allopurinol at the maximum labeled dose (800 mg/dL in the U.S.), or at a medically appropriate lower dose based on dose-limiting toxicity or dose-limiting co-morbidity.
  5. Patient is willing and able to give and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed, including washout).
  6. If the patient is a woman of , she must have had a negative screening serum pregnancy test and must use a medically approved form of during her participation in the protocol. Such methods include oral, injectable or implantable contraceptives; IUDs and barrier contraceptives in combination with spermicide. (If male or surgically sterile, check N/A.)

Exclusion criteria

Exclusion Criteria:

  1. The patient has unstable angina.
  2. The patient has uncontrolled arrhythmia.
  3. The patient has non-compensated congestive heart failure.
  4. The patient has uncontrolled hypertension (above 150/95).
  5. The patient has a history of end stage renal disease requiring dialysis.
  6. The patient has \< 8 g/dL (males) or \< 7 g/dL (females).
  7. The patient is an organ transplant recipient
  8. The patient has had prior treatment with PEG-uricase, or other recombinant uricase, or any concomitant therapy with a PEG-conjugated drug.
  9. The patient has had a gout flare at screening that is resolved for less than one week prior to first treatment with study drug (exclusive of chronic synovitis/ arthritis).
  10. The patient has glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  11. The patient has a history of anaphylactic reaction to a recombinant protein or porcine product, or to PEG.
  12. The patient is pregnant or breast feeding.
  13. The patient has taken an drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study.
  14. The patient has a known allergy to urate oxidase or PEGylated products.
  15. The patient has any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    q2 wks

    8 mg pegloticase every 2 weeks

    Biological: pegloticase

  • Experimental
    q4 wks

    8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)

    Biological: pegloticase

  • Placebo comparator
    placebo

    placebo every 2 weeks

    Other: placebo

Interventions

  • Otherplacebo

    placebo by intravenous infusion every 2 weeks

  • Biologicalpegloticase

    8 mg pegloticase by intravenous infusion

    Also known as: PEG-uricase, Puricase

06

What researchers measure

Primary outcomes

  1. Plasma Uric Acid (PUA) Responder

    PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations \< 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders.

    Time frame: Months 3 and 6

Secondary outcomes

  1. Reduction in Tophus Burden

    percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software.

    Time frame: Baseline and Final Visit (6 months or LOCF)

  2. Percentage of Subjects With Gout Flare Per 3-month Period

    Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period.

    Time frame: Months 1-3 and Months 4-6

  3. Change in Number of Swollen Joints

    Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies.

    Time frame: Baseline and Final Visit (Month 6 or LOCF)

  4. Change in Number of Tender Joints

    Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant

    Time frame: Baseline and Final Visit (Month 6 or LOCF)

  5. Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life

    Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of \> or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of \> or =2.5 units in the PCS is considered a MCID.

    Time frame: Baseline to Final Visit (Month 6 or LOCF)

07

Results

Posted Feb 25, 2011

Participant flow

Rheumatology practices across the US, Canada and Mexico

Randomized
Participant flow — Randomized
Milestoneq2 Wksq4 WksPlacebo
Started908946
Completed858443
Not completed553
Withdrew: Not dosed553
Received Intervention: ITT Population
Participant flow — Received Intervention: ITT Population
Milestoneq2 Wksq4 WksPlacebo
Started858443
Completed595939
Not completed26254
Withdrew: Adverse event15171
Withdrew: Death310
Withdrew: Withdrawal by subject761
Withdrew: Lost to follow-up002
Withdrew: Protocol violation/non-compliance110

Outcome measures

PrimaryPlasma Uric Acid (PUA) Responder

PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations \< 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders.

Time frame:
Months 3 and 6
Reported as:
Number · Participants
Plasma Uric Acid (PUA) Responder
Participantsq2 Wksq4 WksPlacebo
Plasma Uric Acid (PUA) Responder36290
Statistical analysis
  • q2 Wks vs Placebo · Fisher Exact · p = <0.001
  • q4 Wks vs Placebo · Fisher Exact · p = <0.001
SecondaryReduction in Tophus Burden

percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software.

Time frame:
Baseline and Final Visit (6 months or LOCF)
Reported as:
Number · Percent subjects with resolved tophus
Reduction in Tophus Burden
Percent subjects with resolved tophusq2 Wksq4 WksPlacebo
Reduction in Tophus Burden40217
Statistical analysis
  • q2 Wks vs Placebo · Fisher Exact · p = <0.002
  • q4 Wks vs Placebo · Fisher Exact · p = 0.200
SecondaryPercentage of Subjects With Gout Flare Per 3-month Period

Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period.

Time frame:
Months 1-3 and Months 4-6
Reported as:
Number · Percent subjects reporting flares
Percentage of Subjects With Gout Flare Per 3-month Period
Percent subjects reporting flaresq2 Wksq4 WksPlacebo
Months 1-3758154
Months 4-6415667
Statistical analysis
  • q2 Wks vs Placebo · Fisher Exact · p = 0.007
  • q4 Wks vs Placebo · Fisher Exact · p = 0.321
SecondaryChange in Number of Swollen Joints

Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies.

Time frame:
Baseline and Final Visit (Month 6 or LOCF)
Reported as:
Mean · Swollen joints
Change in Number of Swollen Joints
Swollen jointsq2 Wksq4 WksPlacebo
Change in Number of Swollen Joints-5.5 ± 10.47-5.1 ± 7.83-2.6 ± 11.64
Statistical analysis
  • q2 Wks vs Placebo · t-test, 2 sided · p = 0.166
  • q4 Wks vs Placebo · t-test, 2 sided · p = 0.170
SecondaryChange in Number of Tender Joints

Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant

Time frame:
Baseline and Final Visit (Month 6 or LOCF)
Reported as:
Mean · Tender joints
Change in Number of Tender Joints
Tender jointsq2 Wksq4 WksPlacebo
Change in Number of Tender Joints-7.4 ± 11.95-6.1 ± 10.64-1.2 ± 12.30
Statistical analysis
  • q2 Wks vs Placebo · t-test, 2 sided · p = 0.008
  • q4 Wks vs Placebo · t-test, 2 sided · p = 0.024
SecondaryChange in Patient Reported Outcomes of Pain, Physical Function and Quality of Life

Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of \> or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of \> or =2.5 units in the PCS is considered a MCID.

Time frame:
Baseline to Final Visit (Month 6 or LOCF)
Reported as:
Mean · Units on a scale
Change in Patient Reported Outcomes of Pain, Physical Function and Quality of Life
Units on a scaleq2 Wksq4 WksPlacebo
HAQ-VAS Pain-11.4 ± 33.8-6.9 ± 27.01.4 ± 30.0
HAQ-DI-0.22 ± 0.64-0.20 ± 0.550.0 ± 0.41
SF-36 PCS4.4 ± 9.44.9 ± 8.5-0.3 ± 9.0

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
q2 Wks—20/85 (23.5%)69/85 (81.2%)
q4 Wks—19/84 (22.6%)79/84 (94%)
Placebo—5/43 (11.6%)36/43 (83.7%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
Eventq2 Wksq4 WksPlacebo
Infusion Related ReactionGeneral disorders4/857/840/43
GoutMusculoskeletal and connective tissue disorders4/851/842/43
ArrhythmiaCardiac disorders2/850/840/43
Gatrooesophageal Reflux DiseaseGastrointestinal disorders2/850/840/43
PneumoniaInfections and infestations1/851/841/43
Arthritis BacterialInfections and infestations0/850/841/43
Herpes ZosterInfections and infestations0/850/841/43
Perianal AbscessInfections and infestations0/850/841/43
PancreatitisGastrointestinal disorders0/851/841/43
Inguinal Hernia, ObstructiveGastrointestinal disorders0/850/841/43
Most frequent other events
Showing 10 of 33
Most frequent other events
Eventq2 Wksq4 WksPlacebo
Upper Respiratory Tract InfectionInfections and infestations4/854/849/43
ArthralgiaMusculoskeletal and connective tissue disorders6/8515/848/43
DiarrhoeaGastrointestinal disorders9/8514/848/43
Oedema PeripheralGeneral disorders9/8511/846/43
NauseaGastrointestinal disorders10/856/841/43
HeadacheNervous system disorders8/859/844/43
InsomniaPsychiatric disorders5/858/844/43
Muscle SpasmsMusculoskeletal and connective tissue disorders3/855/844/43
FatigueGeneral disorders5/856/844/43
DizzinessNervous system disorders3/857/844/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)q2 Wksq4 WksPlaceboTotal
<=18 years0000
Between 18 and 65 years566531152
>=65 years29191260
Age Continuous
Age Continuous(years)q2 Wksq4 WksPlaceboTotal
Mean56.3 ± 15.5354.5 ± 13.3455.4 ± 12.2155.4 ± 14.01
Sex: Female, Male
Sex: Female, Male(Participants)q2 Wksq4 WksPlaceboTotal
Female1715739
Male686936173
Region of Enrollment
Region of Enrollment(participants)q2 Wksq4 WksPlaceboTotal
United States737739189
Canada1113
Mexico116320
08

Study locations

56 sites
  • UAB Arthritis Clinical Intervention Program
    Birmingham, Alabama 35294, United States
  • University of Arizona Arthritis Center
    Tucson, Arizona 85724, United States
  • NEA Clinic
    Jonesboro, Arkansas 72401, United States
  • UCSD Rheumatology Division
    La Jolla, California 92037-0943, United States
  • Kaiser Permanente Medical Center, Clinical Trials Unit
    San Francisco, California 94118, United States
  • Pacific Arthritis Center Medical Group
    Santa Maria, California 93454, United States
  • E. Robert Harris Medical Corporation
    Whittier, California 90601, United States
  • Agilence Arthritis & Osteoporosis Medical Center
    Whittier, California 90606, United States
  • Arthritis Associates & Osteoporosis Center of Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Veterans Affairs Medical Center
    Washington, District of Columbia 20422, United States
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Malcom Randall VA Medical Center
    Gainesville, Florida 32608, United States
  • Horizon Institute for Clinical Research
    Hollywood, Florida 33021, United States
  • Ocala Rheumatology Research Center
    Ocala, Florida 34474, United States
  • Arthritis & Osteoporosis Treatment Center, PA
    Orange Park, Florida 32073, United States
  • St. Petersburg Arthritis Center
    St. Petersburg, Florida 33703, United States
  • Idaho Arthritis & Osteoporosis Center
    Boise, Idaho 83702, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83401, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Peter A. Holt, M.D.
    Baltimore, Maryland 21239, United States
  • Malamet & Klein, MD, PA
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Fallon Clinic, Inc
    Worcester, Massachusetts 01605, United States
  • Michigan Arthritis Research Center
    Brighton, Michigan 48116, United States
  • Justus J. Fiechtner, MD, PC
    Lansing, Michigan 48910, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • CentraCare Clinic
    St. Cloud, Minnesota 56377, United States
  • Rheumatology Associates of North Jersey
    Teaneck, New Jersey 07666, United States
  • Mount Sinai Medical Center
    New York, New York 10029-6574, United States
  • Duke University Medical Center
    Durham, North Carolina 27302, United States
  • Brody School of Medicine, East Carolina University
    Greenville, North Carolina 27834, United States
  • Physicians East, P.A.
    Greenville, North Carolina 27834, United States
  • Carolina Atthritis Associates
    Wilmington, North Carolina 28401, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • STAT Research, Inc.
    Dayton, Ohio 45402, United States
  • David R. Mandel, MD, Inc.
    Mayfield Village, Ohio 44143, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73139, United States
  • Portland Medical Associates
    Portland, Oregon 97224, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Mid Atlantic Research Assoc.
    Philadelphia, Pennsylvania 19154, United States
  • Rheumatology Associates
    Charleston, South Carolina 29407, United States
  • Piedmont Arthritis, PA
    Greenville, South Carolina 29601, United States
  • AAMR Research Clinic
    Amarillo, Texas 79106, United States
  • Arthritis & Osteoporosis Center of South Texas
    San Antonio, Texas 78232, United States
  • Arthritis & Osteoporosis Clinic Research Center of Central Texas
    Waco, Texas 76708, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Manitoba Clinic
    Winnipeg, Manitoba R3A 1M3, Canada
  • St. Joseph's Health Care
    London, Ontario N6A 4V2, Canada
  • Clinica para el Diagnostico y Tratamiento de las Enfermedades Rheumaticas
    Mexico, D.f., Mexico
  • Hospital General de mexico
    Mexico, D.f., Mexico
  • Antiguo Hospital Civil de Guadalajara
    Guadalajara, Jalisco, Mexico
  • Hospital Civil de Guadalajara
    Guadalajara, Jalisco, Mexico
09

References and documents

Publications

  • Pillinger MH, Fields TR, Yeo AE, Lipsky PE. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. J Rheumatol. 2020 Apr;47(4):605-612. doi: 10.3899/jrheum.190161. Epub 2019 Jun 15. PubMed 31203212 ↗
  • Johnson RJ, Choi HK, Yeo AE, Lipsky PE. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Hypertension. 2019 Jul;74(1):95-101. doi: 10.1161/HYPERTENSIONAHA.119.12727. Epub 2019 May 13. PubMed 31079535 ↗
  • Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497. PubMed 24588936 ↗
  • Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014 Jan 21;7:54. doi: 10.1186/1756-0500-7-54. PubMed 24447425 ↗
  • Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318. PubMed 24286509 ↗
  • Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169. PubMed 21846852 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Oct 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2006
First posted
May 12, 2006
Start
May 2006
Primary completionActual
Oct 2007
CompletionActual
Dec 2007
Results first posted
Feb 25, 2011
Last update
Feb 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00325195
Lead sponsor
Savient Pharmaceuticals
First posted
May 12, 2006
Start date
May 2006
Primary completion
Oct 2007
Completion
Dec 2007
Results posted
Feb 25, 2011
Last update
Feb 28, 2011

Study contacts

Medical Director, MD
study director · Savient Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion